Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

CD43 functions as a CD47 independent “don't eat me” signal and novel immune checkpoint in AML

Yun Li, Chuqi Wang, Javier Sanmartín‑Martínez, Bob vangasteren, Jordan Yong Ming Tan, Shaista Jasdanwala, Karanpreet Bhatia, Ankit Jana, Xiao Xian Lin, Yuhan Wang, Peter Miller, Adam Sperling, Anna Marneth, Shruti Bhatt

Blood (2025) 146 (Supplement 1): 5025.

https://doi.org/10.1182/blood-2025-5025

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Shahrier Hossain, Adam Sperling, Jacob Laubach, Shannon Miller, Pedro Vianna, Emily Simpson, Madison Chuma, Brendan Fink, Samantha Geberth, Emily Magnavita, Jack Khouri, James Hoffman, Jonathan Kaufman, Vaishali Sanchorawala, Raymond Comenzo, Giada Bianchi

Blood (2025) 146 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2025-5808

Published: 2025

Journal Articles

Engineering dual-specificity PPM1D inhibitors to enhance therapeutic response and overcome chemoresistance in TP53-mutant malignancies

Peter Miller, Ygang Tang, David McKinney, Mikolaj Slabicki, Rishi Puram, Adam Sperling, Michelle Lee, Jennifer Roth, Alexandra Gould, Eugene Oh

Blood (2025) 146 (Supplement 1): 5048.

https://doi.org/10.1182/blood-2025-5048

Published: 2025

Journal Articles

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Blood (2025) 146 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2025-2237

Published: 2025

Journal Articles

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Blood (2025) 146 (Supplement 1): 256.

https://doi.org/10.1182/blood-2025-256

Published: 2025

Journal Articles

Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM

Rao Prabhala, Lakshmi Bhavani Potluri, Srikanth Talluri, Hannah Seah, Vaishnavi Bade, Sahan Vangala, Mehmet Samur, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa, Sinead Dolan, David Pearson, Pedro Milanez-Almeida, Jennifer Mataraza, Jerome Ritz, Dexiu BU, Marc Credi, Adam Sperling, Nikhil Munshi

Blood (2025) 146 (Supplement 1): 5713.

https://doi.org/10.1182/blood-2025-5713

Published: 2025

Journal Articles

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Blood (2025) 146 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2025-3930

Published: 2025

Journal Articles

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

Blood (2025) 146 (Supplement 1): 261.

https://doi.org/10.1182/blood-2025-261

Published: 2025

Journal Articles

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Zohaib Ahmed, Walid Hamouche, Shonali Midha, Yuxin Liu, Adam Sperling, Clifton Mo, Jacob Laubach, Paul Richardson, Nikhil Munshi, Omar Nadeem

Blood (2025) 146 (Supplement 1): 7525.

https://doi.org/10.1182/blood-2025-7525

Published: 2025

Journal Articles

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Narsis Attar, Rajib Shome, Mehmet Samur, Joshua Gustine, Charlotte Graham, Kathleen ME Gallagher, Agustin Busse, Deshea L Harris, Diana Cirstea, Andrew Yee, Andrew Branagan, Marcela Maus, Matthew Frigault, Nikhil Munshi, Adam Sperling, Noopur Raje

Blood (2025) 146 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2025-5764

Published: 2025

Journal Articles

Clonal hematopoiesis and lung adenocarcinoma pathogenesis

Peter Miller, Tiziana Parisi, Adam Sperling, Christopher Gibson, Marie McConkey, Benjamin Ebert, Tyler Jacks

Blood (2025) 146 (Supplement 1): 4940.

https://doi.org/10.1182/blood-2025-4940

Published: 2025

Journal Articles

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Blood (2025) 146 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2025-3921

Published: 2025

Journal Articles

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Blood (2025) 146 (Supplement 1): 4014.

https://doi.org/10.1182/blood-2025-4014

Published: 2025

Journal Articles

Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients

Naim Rashid, PhD, Stephane Minvielle, Florence Magrangeas, Mehmet Kemal Samur, PhD, Alice Clynen, PhD, Adam Sperling, MD PhD, Yu-Tzu Tai, PhD, Mariateresa Fulciniti, PhD, Paul G. Richardson, Michel Attal, Philippe Moreau, Kenneth C. Anderson, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 638.

https://doi.org/10.1182/blood.V124.21.638.638

Published: 2014

Journal Articles

Differential and Limited Expression of Mutant Alleles in Multiple Myeloma

Adam Sperling, MD PhD, Naim Rashid, PhD, Niccolo Bolli, MD PhD, David Wedge, PhD, Peter Van Loo, PhD, Yu-Tzu Tai, Masood Shammas, PhD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, P Andrew Futreal, Kenneth C. Anderson, Herve Avet-loiseau, Peter J. Campbell, PhD, Giovanni Parmigiani, PhD, Nikhil Munshi

Blood (2014) 124 (21): 2007.

https://doi.org/10.1182/blood.V124.21.2007.2007

Published: 2014

Journal Articles

Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2

Blood (2014) 124 (21): 4714.

https://doi.org/10.1182/blood.V124.21.4714.4714

Published: 2014

Journal Articles

A Next Generation Sequencing-Based Approach to Detect Gene Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma

Niccolo Bolli, MD PhD, Graham R Bignell, PhD, Peter Ganly, BMBCh, PhD, Elli Papaemmanuil, PhD, Herve Avet-Loiseau, Adam Sperling, MD PhD, Stephane Minvielle, Peter J Campbell, PhD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3364.

https://doi.org/10.1182/blood.V124.21.3364.3364

Published: 2014

Journal Articles

Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma

Mehmet Kemal Samur, PhD, Naim Rashid, PhD, Alice Cleynen, PhD, Mariateresa Fulciniti, PhD, Adam Sperling, MD PhD, Stephane Minvielle, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 642.

https://doi.org/10.1182/blood.V124.21.642.642

Published: 2014

Journal Articles

Multiple Myeloma Cells Express IL-17A Creating An Autocrine Loop: An Attractive Therapeutic Target

Rao H. Prabhala, Ph.D., Mariateresa Fulcinitti, PhD, Dheeraj Pelluru, PhD, Harsha K. Prabhala, MS, Naim Rashid, PhD, Adam Sperling, MD, PhD, Puru Nanjappa, MS, Saem Lee, B.A., Andreea Negroiu, MD, Suzan Lazo-Kallanian, BS, Aditya Munshi, MD, Paul G. Richardson, MD, John Daley, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2013) 122 (21): 3113.

https://doi.org/10.1182/blood.V122.21.3113.3113

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

CD43 functions as a CD47 independent “don't eat me” signal and novel immune checkpoint in AML

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Engineering dual-specificity PPM1D inhibitors to enhance therapeutic response and overcome chemoresistance in TP53-mutant malignancies

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Clonal hematopoiesis and lung adenocarcinoma pathogenesis

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients

Differential and Limited Expression of Mutant Alleles in Multiple Myeloma

Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2

A Next Generation Sequencing-Based Approach to Detect Gene Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma

Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma

Multiple Myeloma Cells Express IL-17A Creating An Autocrine Loop: An Attractive Therapeutic Target

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only